VitaDAO Secures $4.1M Investment from Pfizer Ventures for Longevity Studies

Pfizer Ventures Invests in VitaDAO's Longevity Research with $4.1M Funding

VitaDAO, a Decentralized Autonomous Organization (DAO) focused on longevity research, has closed a $4.1 million funding round led by Pfizer Ventures.

The funding round also includes contributions from Shine Capital, L1 Digital, BeakerDAO, Spaceship DAO, former Coinbase CTO Balaji Srinivasan and Retro Biosciences’ Joe Betts-LaCroix.

VitaDAO was founded in 2021 with the aim of funding research into diseases of aging and cellular biology, and has deployed over $3.5 million towards these goals.

The latest funds will be used to fund longevity research projects and to incubate VitaDAO’s first biotech startup. The group is governed by its native VITA token, and holders can vote on which projects to support.

VitaDAO aims to move beyond physical locations to create “a potential future sovereignty network” as a community with its democratic governance structure.

The overlap between the crypto industry and longevity research is due to the crypto community’s desire to break down barriers and find new solutions to problems, including aging.


Judith Faith has been writing about cryptocurrencies and blockchain technology for over five years. She is well versed in the industry and has an extensive network of industry contacts. She is also a frequent contributor to various cryptocurrency publications. With her vast knowledge and experience, she is able to provide insightful and valuable content to her readers. Judith is also an active investor in the cryptocurrency space and has a vested interest in the success of the industry.